User profiles for P. Sharma

Priyanka Sharma

- Verified email at srmist.edu.in - Cited by 22256

Dr. Pallavi Sharma

- Verified email at cug.ac.in - Cited by 11484

Piyush Sharma

- Verified email at google.com - Cited by 10014

[PDF][PDF] Sharma 4

P Sharma, MV Kimothi, P Mathur, M Ankit - 2023 - wjpr.s3.ap-south-1.amazonaws.com
“Any response to a drug which is noxious, unintended & which occurs at dose normally
used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of …

[HTML][HTML] Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions

P Sharma, AB Jha, RS Dubey, M Pessarakli - Journal of botany, 2012 - hindawi.com
Reactive oxygen species (ROS) are produced as a normal product of plant cellular
metabolism. Various environmental stresses lead to excessive production of ROS causing …

The future of immune checkpoint therapy

P Sharma, JP Allison - Science, 2015 - science.org
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor
immune responses, has led to important clinical advances and provided a new weapon …

[HTML][HTML] Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

P Sharma, JP Allison - Cell, 2015 - cell.com
Research in two fronts has enabled the development of therapies that provide significant
benefit to cancer patients. One area stems from a detailed knowledge of mutations that activate …

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

…, NJ Ajami, JF Petrosino, MT Tetzlaff, P Sharma… - Science, 2018 - science.org
Preclinical mouse models suggest that the gut microbiome modulates tumor response to
checkpoint blockade immunotherapy; however, this has not been well-characterized in human …

[HTML][HTML] Nivolumab versus everolimus in advanced renal-cell carcinoma

…, JS Simon, LA Xu, IM Waxman, P Sharma - … England Journal of …, 2015 - Mass Medical Soc
… The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to
0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective …

[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma

…, M Wind-Rotolo, J Doan, P Sharma… - … England Journal of …, 2018 - Mass Medical Soc
… ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001),
and … ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified …

Shifting the limits in wheat research and breeding using a fully annotated reference genome

…, OP Gupta, S Jindal, P Kaur, P Malik, P Sharma… - Science, 2018 - science.org
INTRODUCTION Wheat (Triticum aestivum L.) is the most widely cultivated crop on Earth,
contributing about a fifth of the total calories consumed by humans. Consequently, wheat …

The human cell atlas

…, TN Schumacher, A Shalek, E Shapiro, P Sharma… - elife, 2017 - elifesciences.org
10.7554/eLife.27041.001 The recent advent of methods for high-throughput single-cell
molecular profiling has catalyzed a growing sense in the scientific community that the time is ripe …

[PDF][PDF] Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

…, SV Novitskiy, A De Jesus-Acosta, P Sharma, P Heidari… - Cancer cell, 2014 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal
myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the …